Cargando...
Advances in Immunotherapy for Cervical Cancer
PURPOSE: Novel therapies are needed for the treatment of recurrent cervical cancer. The best chemotherapy regimen to date has a response rate of 48% with an overall survival of 17 months, with limited options for second-line chemotherapy. Immunotherapy can induce a strong immune response in cervical...
Gardado en:
| Publicado en: | Curr Opin Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7748319/ https://ncbi.nlm.nih.gov/pubmed/32740092 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0000000000000663 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|